Page 17 - Xlife Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Xlife Sciences AG (XLS): Antiviral drug candidate Promising medical drug against Covid-19 and flu viruses A portfolio project of Xlife Sciences AG (XLS) is developing a promising drug candidate against SARS-CoV-2 as well as other flu viruses. The active ingredient inhibits the viral replication and acts against infection related inflammatory processes. It is already in use in humans. Research Development is actively looking for Covid-19 therapies around the world. In this way, the aim is to focus on reducing viral replication in early stages and to treat inflammatory effects at a later stage....

Xlife Sciences AG: Transaction with Baliopharm AG Search jobs Xlife Sciences AG / Key word(s): Contract Xlife Sciences AG: Transaction with Baliopharm AG 08-Jan-2021 / 06:47 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Xlife Sciences AG: Transaction with Baliopharm AG License Deal of 300 million euros successfully completed Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, loc...

Xlife Sciences AG: Exit of a project company More than 20 million euros transaction completed Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates. Xlife Sciences AG will exceed its earnings exp...